Shareholdings
| Concept |
As at 2025-03-31 |
As at 2025-03-31 |
As at 2025-03-31 |
As at 2025-03-31 |
As at 2025-03-31 |
As at 2025-03-31 |
As at 2025-03-31 |
As at 2025-03-31 |
As at 2025-03-31 |
As at 2025-03-31 |
As at 2025-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
As at 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholdings | ||||||||||||||||||||||
| Second largest holding company | ||||||||||||||||||||||
| Details of specified investment shares held for purposes other than pure investment | ||||||||||||||||||||||
| Issue |
澁谷工業㈱
|
久光製薬㈱
|
㈱北國フィナンシャルホールディングス
|
㈱クスリのアオキホールディングス
|
大塚ホールディングス㈱
|
キヤノン㈱
|
第一三共㈱
|
参天製薬㈱
|
小野薬品工業㈱
|
明治ホールディングス㈱
|
㈱ファルコホールディングス
|
— | — | — | — | — | — | — | — | — | — | — |
| Number of shares |
24,010
xbrli:shares
|
78,836
xbrli:shares
|
16,621
xbrli:shares
|
1,260,000
xbrli:shares
|
1,600,000
xbrli:shares
|
12,233
xbrli:shares
|
236,040
xbrli:shares
|
— |
159,365
xbrli:shares
|
15,404
xbrli:shares
|
56,746
xbrli:shares
|
1,260,000
xbrli:shares
|
21,422
xbrli:shares
|
15,404
xbrli:shares
|
159,365
xbrli:shares
|
51,778
xbrli:shares
|
236,040
xbrli:shares
|
1,600,000
xbrli:shares
|
16,621
xbrli:shares
|
31,295
xbrli:shares
|
— |
76,366
xbrli:shares
|
| Number of shares (Not disclosed as below threshold) | — | — | — | — | — | — | — |
*
|
— | — | — | — | — | — | — | — | — | — | — | — |
*
|
— |
| Carrying amount |
76,000,000
JPY
|
319,000,000
JPY
|
97,000,000
JPY
|
4,284,000,000
JPY
|
12,404,000,000
JPY
|
56,000,000
JPY
|
828,000,000
JPY
|
— |
255,000,000
JPY
|
50,000,000
JPY
|
131,000,000
JPY
|
3,986,000,000
JPY
|
75,000,000
JPY
|
52,000,000
JPY
|
391,000,000
JPY
|
121,000,000
JPY
|
1,127,000,000
JPY
|
10,096,000,000
JPY
|
84,000,000
JPY
|
48,000,000
JPY
|
— |
303,000,000
JPY
|
| Carrying amount (Not disclosed as below threshold) | — | — | — | — | — | — | — |
*
|
— | — | — | — | — | — | — | — | — | — | — | — |
*
|
— |
| Purpose of shareholding, overview of business alliance, quantitative effects of shareholding and reason for increase in number of shares |
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１・株式累積投資
|
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１・取引先持株会会員
|
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１
|
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１
|
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１
|
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１
|
・良好な取引関係の維持発展・当社グループの取引先 ・検証実施(注)１
|
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１
|
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１
|
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１
|
・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１・株式累積投資
|
— | — | — | — | — | — | — | — | — | — | — |
| Whether issuer of aforementioned shares holds reporting company's shares |
無
|
有
|
無
|
無
|
無(注)３
|
無
|
無(注)３
|
無
|
有
|
無(注)３
|
無
|
— | — | — | — | — | — | — | — | — | — | — |